

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)*

Eikon Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value \$0.0001 per share

(Title of Class of Securities)

(CUSIP Number)

09/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
- ☒ Rule 13d-1(c)
- ☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons
	Abu Dhabi Investment Authority
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a) ☐ (b)
3	Sec Use Only
	Citizenship or Place of Organization
4	UNITED ARAB EMIRATES

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power
	0.00	
		Shared Voting Power
	6	
	1,147,138.00	
		Sole Dispositive Power
	7	
	0.00	
		Shared Dispositive Power
	8	
	1,147,138.00	
	Aggregate Amount Beneficially Owned by Each Reporting Person	
9	1,147,138.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	
	☐	
11	Percent of class represented by amount in row (9)	
	2.1 %	
12	Type of Reporting Person (See Instructions)	
	OO	

Comment for Type of Reporting Person: (1) The percent calculation is based on 54,165,030 shares of Common Stock outstanding as of August 3, 2026, as disclosed in Eikon Therapeutics, Inc.'s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026, filed with the U.S. Securities and Exchange Commission (the "SEC") on August 13, 2026 (the "Form 10-Q").

SCHEDULE 13G

CUSIP No.

	Names of Reporting Persons	
1	Platinum Falcon B 2018 RSC Limited	
	Check the appropriate box if a member of a Group (see instructions)	
2	☐ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization	
	UNITED ARAB EMIRATES	
	Sole Voting Power	
	5	
	0.00	
Number of Shares Beneficially Owned by Each Reporting Person With:	6	Shared Voting Power
	1,147,138.00	
		Sole Dispositive Power
	7	
	0.00	
		Shared Dispositive Power
	8	
	1,147,138.00	
9	Aggregate Amount Beneficially Owned by Each Reporting Person	

1,147,138.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10



Percent of class represented by amount in row (9)

11

2.1 %

Type of Reporting Person (See Instructions)

12

CO

Comment for Type of Reporting Person: (1) Platinum Falcon B 2018 RSC Limited ("Platinum Falcon") is the direct owner of 1,147,138 of the shares of Common Stock reported herein. Platinum Falcon is a wholly owned subsidiary of Abu Dhabi Investment Authority. Pursuant to the rules and regulations of the SEC, Abu Dhabi Investment Authority may be deemed to be the beneficial owner of the shares of Common Stock directly held by Platinum Falcon. (2) The percent calculation is based on 54,165,030 shares of Common Stock outstanding as of August 3, 2026, as disclosed in Eikon Therapeutics, Inc.'s Form 10-Q.

SCHEDULE 13G

Item 1.

Name of issuer:

(a)

Eikon Therapeutics, Inc.

Address of issuer's principal executive offices:

(b)

230 Harriet Tubman Way, Millbrae CA 94030

Item 2.

Name of person filing:

(a)

This Schedule 13G/A is being filed on behalf of the following: 1. Abu Dhabi Investment Authority 2. Platinum Falcon B 2018 RSC Limited

Address or principal business office or, if none, residence:

(b)

The principal business address of each of the Reporting Persons is as follows: 1. 211 Corniche Street P.O. Box 3600 Abu Dhabi, United Arab Emirates 3600 2. Level 26, Al Khatem Tower Abu Dhabi Global Market Square Al Maryah Island, Abu Dhabi United Arab Emirates

Citizenship:

(c)

1. Abu Dhabi Investment Authority (ADIA) is a public institution established by the Government of the Emirate of Abu Dhabi in 1976 as an independent investment institution. 2. Platinum Falcon B 2018 RSC Limited is a restricted scope company organized under the laws of the Abu Dhabi Global Market, Abu Dhabi, United Arab Emirates.

Title of class of securities:

(d)

Common Stock, par value \$0.0001 per share

(e)

CUSIP No.:

Item 4.

Ownership

Amount beneficially owned:

(a)

See responses to Item 9 on each cover page.

Percent of class:

(b)

See responses to Item 11 on each cover page. %

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

See responses to Item 5 on each cover page.

(ii) Shared power to vote or to direct the vote:

See responses to Item 6 on each cover page.

(iii) Sole power to dispose or to direct the disposition of:

See responses to Item 7 on each cover page.

(iv) Shared power to dispose or to direct the disposition of:

See responses to Item 8 on each cover page.

Item 5. Ownership of 5 Percent or Less of a Class.

☒ Ownership of 5 percent or less of a class

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Abu Dhabi Investment Authority

Signature: /s/ Saif Almashghouni

Name/Title: Saif Almashghouni / Authorized Signatory

Date: 10/02/2026

Signature: /s/ Ahmed AlNeyadi

Name/Title: Ahmed AlNeyadi / Authorized Signatory

Date: 10/02/2026

Platinum Falcon B 2018 RSC Limited

Signature: /s/ Saif Almashghouni

Name/Title: Saif Almashghouni / Authorized Signatory

Date: 10/02/2026

Signature: /s/ Ahmed AlNeyadi

Name/Title: Ahmed AlNeyadi / Authorized Signatory

Date: 10/02/2026